Presentations highlight advances in MRD, precision oncology, and real-world evidence across solid tumors and hematologic malignancies
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences:...
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know
3 Russell 2000 Stocks We’re Skeptical Of
3 Reasons NEO is Risky and 1 Stock to Buy Instead
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call
NEO Q1 Deep Dive: High-Value Test Expansion and Commercial Execution Drive Oncology Growth
NeoGenomics’s (NASDAQ:NEO) Q1 CY2026: Beats On Revenue
First quarter total revenue increased 11% YoY to $187 million; Clinical revenue grew 14%, including NGS growth of 26%; Company announces...